RT Journal Article
SR Electronic
T1 Cross-modal sensory boosting to improve high-frequency hearing loss
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.01.23290351
DO 10.1101/2023.06.01.23290351
A1 Kohler, Izzy
A1 Perrotta, Michael V.
A1 Ferreira, Tiago
A1 Eagleman, David M.
YR 2023
UL http://medrxiv.org/content/early/2023/06/06/2023.06.01.23290351.abstract
AB High frequency hearing loss is one of the most common problems in the aging population and with those who have a history of exposure to loud noises. To address high-frequency hearing loss, we developed a multi-motor wristband that uses machine learning to listen for specific high frequency phonemes. The wristband vibrates in spatially unique locations to represent which phoneme was present, in real time. We recruited 16 participants with high frequency hearing loss and asked them to wear the wristband for six weeks. Their degree of disability associated with hearing loss was measured weekly using the Abbreviated Profile of Hearing Aid Benefit (APHAB). Our findings show that vibrotactile sensory substitution delivered by a wristband that produces spatially distinguishable vibrations in correspondence with high frequency phonemes helps individuals with high frequency hearing loss improve their understanding of verbal communication. We find that vibrotactile feedback provides benefits whether or not a person wears hearing aids, albeit in slightly different ways. Finally, our results also demonstrate that individuals with the greatest difficulty understanding speech prior to the study experience the greatest amount of benefit from vibrotactile feedback.Competing Interest StatementBesides Stanford University, some of the authors are or were employed at Neosensory, Inc, the makers of this device.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by Solutions IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.